The global market for Non-Insulin Hypoglycemic Drug was valued at US$ 23310 million in the year 2024 and is projected to reach a revised size of US$ 30760 million by 2031, growing at a CAGR of 4.1% during the forecast period.

Non-Insulin Hypoglycemic Drug Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-Insulin Hypoglycemic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Hypoglycemic Drug.

The Non-Insulin Hypoglycemic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Insulin Hypoglycemic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Insulin Hypoglycemic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Non-Insulin Hypoglycemic Drug Market Report

Report Metric	Details
Report Name	Non-Insulin Hypoglycemic Drug Market
Accounted market size in year	US$ 23310 million
Forecasted market size in 2031	US$ 30760 million
CAGR	4.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Sulfonylureas Meglitinides Biguanides Thiazolidinediones Alpha Glucosidase Inhibitors Others
Segment by Application	Hospital Pharmacies Retail Pharmacies
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical, Luye Pharma Group, Eurofarma, Geropharm, Alkem Labs, Jiangsu Hansoh Pharmaceutical, Novo Nordisk, Emisphere, Uni-Bio Science Group, Takeda, 3SBio, Jiangsu Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Non-Insulin Hypoglycemic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Non-Insulin Hypoglycemic Drug Market growing?

Ans: The Non-Insulin Hypoglycemic Drug Market witnessing a CAGR of 4.1% during the forecast period 2025-2031.

What is the Non-Insulin Hypoglycemic Drug Market size in 2031?

Ans: The Non-Insulin Hypoglycemic Drug Market size in 2031 will be US$ 30760 million.

Who are the main players in the Non-Insulin Hypoglycemic Drug Market report?

Ans: The main players in the Non-Insulin Hypoglycemic Drug Market are GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical, Luye Pharma Group, Eurofarma, Geropharm, Alkem Labs, Jiangsu Hansoh Pharmaceutical, Novo Nordisk, Emisphere, Uni-Bio Science Group, Takeda, 3SBio, Jiangsu Hengrui Medicine

What are the Application segmentation covered in the Non-Insulin Hypoglycemic Drug Market report?

Ans: The Applications covered in the Non-Insulin Hypoglycemic Drug Market report are Hospital Pharmacies, Retail Pharmacies

What are the Type segmentation covered in the Non-Insulin Hypoglycemic Drug Market report?

Ans: The Types covered in the Non-Insulin Hypoglycemic Drug Market report are Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, Alpha Glucosidase Inhibitors, Others

1 Non-Insulin Hypoglycemic Drug Market Overview

1.1 Product Definition

1.2 Non-Insulin Hypoglycemic Drug by Type

1.2.1 Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 Sulfonylureas

1.2.3 Meglitinides

1.2.4 Biguanides

1.2.5 Thiazolidinediones

1.2.6 Alpha Glucosidase Inhibitors

1.2.7 Others

1.3 Non-Insulin Hypoglycemic Drug by Application

1.3.1 Global Non-Insulin Hypoglycemic Drug Market Value by Application (2024 VS 2031)

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.4 Global Non-Insulin Hypoglycemic Drug Market Size Estimates and Forecasts

1.4.1 Global Non-Insulin Hypoglycemic Drug Revenue 2020-2031

1.4.2 Global Non-Insulin Hypoglycemic Drug Sales 2020-2031

1.4.3 Global Non-Insulin Hypoglycemic Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Non-Insulin Hypoglycemic Drug Market Competition by Manufacturers

2.1 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Non-Insulin Hypoglycemic Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Non-Insulin Hypoglycemic Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application

2.7 Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Date of Enter into This Industry

2.8 Global Non-Insulin Hypoglycemic Drug Market Competitive Situation and Trends

2.8.1 Global Non-Insulin Hypoglycemic Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Non-Insulin Hypoglycemic Drug Players Market Share by Revenue

2.8.3 Global Non-Insulin Hypoglycemic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Non-Insulin Hypoglycemic Drug Market Scenario by Region

3.1 Global Non-Insulin Hypoglycemic Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2020-2031

3.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2020-2025

3.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2026-2031

3.3 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2020-2031

3.3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2020-2025

3.3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2026-2031

3.4 North America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country

3.4.1 North America Non-Insulin Hypoglycemic Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2020-2031)

3.4.3 North America Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country

3.5.1 Europe Non-Insulin Hypoglycemic Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2020-2031)

3.5.3 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Non-Insulin Hypoglycemic Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Non-Insulin Hypoglycemic Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country

3.7.1 Latin America Non-Insulin Hypoglycemic Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2020-2031)

3.7.3 Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2020-2031)

4.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2020-2025)

4.1.2 Global Non-Insulin Hypoglycemic Drug Sales by Type (2026-2031)

4.1.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2020-2031)

4.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2020-2031)

4.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2020-2025)

4.2.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2026-2031)

4.2.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2020-2031)

4.3 Global Non-Insulin Hypoglycemic Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2020-2031)

5.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2020-2025)

5.1.2 Global Non-Insulin Hypoglycemic Drug Sales by Application (2026-2031)

5.1.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2020-2031)

5.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2020-2031)

5.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2020-2025)

5.2.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2026-2031)

5.2.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2020-2031)

5.3 Global Non-Insulin Hypoglycemic Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 GSK

6.1.1 GSK Company Information

6.1.2 GSK Description and Business Overview

6.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio

6.1.5 GSK Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Sumitomo Dainippon Pharma

6.3.1 Sumitomo Dainippon Pharma Company Information

6.3.2 Sumitomo Dainippon Pharma Description and Business Overview

6.3.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio

6.3.5 Sumitomo Dainippon Pharma Recent Developments/Updates

6.4 Intarcia Therapeutics

6.4.1 Intarcia Therapeutics Company Information

6.4.2 Intarcia Therapeutics Description and Business Overview

6.4.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio

6.4.5 Intarcia Therapeutics Recent Developments/Updates

6.5 Servier

6.5.1 Servier Company Information

6.5.2 Servier Description and Business Overview

6.5.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio

6.5.5 Servier Recent Developments/Updates

6.6 Pfizer

6.6.1 Pfizer Company Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio

6.6.5 Pfizer Recent Developments/Updates

6.7 Merck

6.7.1 Merck Company Information

6.7.2 Merck Description and Business Overview

6.7.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio

6.7.5 Merck Recent Developments/Updates

6.8 Dong-A Pharmaceutical

6.8.1 Dong-A Pharmaceutical Company Information

6.8.2 Dong-A Pharmaceutical Description and Business Overview

6.8.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio

6.8.5 Dong-A Pharmaceutical Recent Developments/Updates

6.9 Luye Pharma Group

6.9.1 Luye Pharma Group Company Information

6.9.2 Luye Pharma Group Description and Business Overview

6.9.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio

6.9.5 Luye Pharma Group Recent Developments/Updates

6.10 Eurofarma

6.10.1 Eurofarma Company Information

6.10.2 Eurofarma Description and Business Overview

6.10.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio

6.10.5 Eurofarma Recent Developments/Updates

6.11 Geropharm

6.11.1 Geropharm Company Information

6.11.2 Geropharm Description and Business Overview

6.11.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio

6.11.5 Geropharm Recent Developments/Updates

6.12 Alkem Labs

6.12.1 Alkem Labs Company Information

6.12.2 Alkem Labs Description and Business Overview

6.12.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio

6.12.5 Alkem Labs Recent Developments/Updates

6.13 Jiangsu Hansoh Pharmaceutical

6.13.1 Jiangsu Hansoh Pharmaceutical Company Information

6.13.2 Jiangsu Hansoh Pharmaceutical Description and Business Overview

6.13.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio

6.13.5 Jiangsu Hansoh Pharmaceutical Recent Developments/Updates

6.14 Novo Nordisk

6.14.1 Novo Nordisk Company Information

6.14.2 Novo Nordisk Description and Business Overview

6.14.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio

6.14.5 Novo Nordisk Recent Developments/Updates

6.15 Emisphere

6.15.1 Emisphere Company Information

6.15.2 Emisphere Description and Business Overview

6.15.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.15.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio

6.15.5 Emisphere Recent Developments/Updates

6.16 Uni-Bio Science Group

6.16.1 Uni-Bio Science Group Company Information

6.16.2 Uni-Bio Science Group Description and Business Overview

6.16.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.16.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio

6.16.5 Uni-Bio Science Group Recent Developments/Updates

6.17 Takeda

6.17.1 Takeda Company Information

6.17.2 Takeda Description and Business Overview

6.17.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.17.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio

6.17.5 Takeda Recent Developments/Updates

6.18 3SBio

6.18.1 3SBio Company Information

6.18.2 3SBio Description and Business Overview

6.18.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.18.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio

6.18.5 3SBio Recent Developments/Updates

6.19 Jiangsu Hengrui Medicine

6.19.1 Jiangsu Hengrui Medicine Company Information

6.19.2 Jiangsu Hengrui Medicine Description and Business Overview

6.19.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2020-2025)

6.19.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio

6.19.5 Jiangsu Hengrui Medicine Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Non-Insulin Hypoglycemic Drug Industry Chain Analysis

7.2 Non-Insulin Hypoglycemic Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Non-Insulin Hypoglycemic Drug Production Mode & Process Analysis

7.4 Non-Insulin Hypoglycemic Drug Sales and Marketing

7.4.1 Non-Insulin Hypoglycemic Drug Sales Channels

7.4.2 Non-Insulin Hypoglycemic Drug Distributors

7.5 Non-Insulin Hypoglycemic Drug Customer Analysis

8 Non-Insulin Hypoglycemic Drug Market Dynamics

8.1 Non-Insulin Hypoglycemic Drug Industry Trends

8.2 Non-Insulin Hypoglycemic Drug Market Drivers

8.3 Non-Insulin Hypoglycemic Drug Market Challenges

8.4 Non-Insulin Hypoglycemic Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sumitomo Dainippon Pharma

Intarcia Therapeutics

Servier

Merck

Dong-A Pharmaceutical

Eurofarma

Geropharm

Alkem Labs

Jiangsu Hansoh Pharmaceutical

Novo Nordisk

Emisphere

Uni-Bio Science Group

Takeda

3SBio Inc

Jiangsu Hengrui Medicine

List of Tables

Table 1. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Non-Insulin Hypoglycemic Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Non-Insulin Hypoglycemic Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Non-Insulin Hypoglycemic Drug Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Non-Insulin Hypoglycemic Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application

Table 12. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Non-Insulin Hypoglycemic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Hypoglycemic Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Non-Insulin Hypoglycemic Drug Sales by Region (2020-2025) & (K Units)

Table 18. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2020-2025)

Table 19. Global Non-Insulin Hypoglycemic Drug Sales by Region (2026-2031) & (K Units)

Table 20. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2026-2031)

Table 21. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Non-Insulin Hypoglycemic Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Non-Insulin Hypoglycemic Drug Sales by Country (2020-2025) & (K Units)

Table 27. North America Non-Insulin Hypoglycemic Drug Sales by Country (2026-2031) & (K Units)

Table 28. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Non-Insulin Hypoglycemic Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2020-2025) & (K Units)

Table 32. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2026-2031) & (K Units)

Table 33. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Type (2020-2025)

Table 51. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Type (2026-2031)

Table 52. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2020-2025)

Table 53. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2026-2031)

Table 54. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2020-2025)

Table 59. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2026-2031)

Table 60. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Application (2020-2025)

Table 61. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Application (2026-2031)

Table 62. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2020-2025)

Table 63. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2026-2031)

Table 64. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2020-2025)

Table 69. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2026-2031)

Table 70. GSK Company Information

Table 71. GSK Description and Business Overview

Table 72. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. GSK Non-Insulin Hypoglycemic Drug Product

Table 74. GSK Recent Developments/Updates

Table 75. Eli Lilly Company Information

Table 76. Eli Lilly Description and Business Overview

Table 77. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Eli Lilly Non-Insulin Hypoglycemic Drug Product

Table 79. Eli Lilly Recent Developments/Updates

Table 80. Sumitomo Dainippon Pharma Company Information

Table 81. Sumitomo Dainippon Pharma Description and Business Overview

Table 82. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product

Table 84. Sumitomo Dainippon Pharma Recent Developments/Updates

Table 85. Intarcia Therapeutics Company Information

Table 86. Intarcia Therapeutics Description and Business Overview

Table 87. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product

Table 89. Intarcia Therapeutics Recent Developments/Updates

Table 90. Servier Company Information

Table 91. Servier Description and Business Overview

Table 92. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Servier Non-Insulin Hypoglycemic Drug Product

Table 94. Servier Recent Developments/Updates

Table 95. Pfizer Company Information

Table 96. Pfizer Description and Business Overview

Table 97. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Pfizer Non-Insulin Hypoglycemic Drug Product

Table 99. Pfizer Recent Developments/Updates

Table 100. Merck Company Information

Table 101. Merck Description and Business Overview

Table 102. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Merck Non-Insulin Hypoglycemic Drug Product

Table 104. Merck Recent Developments/Updates

Table 105. Dong-A Pharmaceutical Company Information

Table 106. Dong-A Pharmaceutical Description and Business Overview

Table 107. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product

Table 109. Dong-A Pharmaceutical Recent Developments/Updates

Table 110. Luye Pharma Group Company Information

Table 111. Luye Pharma Group Description and Business Overview

Table 112. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product

Table 114. Luye Pharma Group Recent Developments/Updates

Table 115. Eurofarma Company Information

Table 116. Eurofarma Description and Business Overview

Table 117. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Eurofarma Non-Insulin Hypoglycemic Drug Product

Table 119. Eurofarma Recent Developments/Updates

Table 120. Geropharm Company Information

Table 121. Geropharm Description and Business Overview

Table 122. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Geropharm Non-Insulin Hypoglycemic Drug Product

Table 124. Geropharm Recent Developments/Updates

Table 125. Alkem Labs Company Information

Table 126. Alkem Labs Description and Business Overview

Table 127. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Alkem Labs Non-Insulin Hypoglycemic Drug Product

Table 129. Alkem Labs Recent Developments/Updates

Table 130. Jiangsu Hansoh Pharmaceutical Company Information

Table 131. Jiangsu Hansoh Pharmaceutical Description and Business Overview

Table 132. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product

Table 134. Jiangsu Hansoh Pharmaceutical Recent Developments/Updates

Table 135. Novo Nordisk Company Information

Table 136. Novo Nordisk Description and Business Overview

Table 137. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 138. Novo Nordisk Non-Insulin Hypoglycemic Drug Product

Table 139. Novo Nordisk Recent Developments/Updates

Table 140. Emisphere Company Information

Table 141. Emisphere Description and Business Overview

Table 142. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 143. Emisphere Non-Insulin Hypoglycemic Drug Product

Table 144. Emisphere Recent Developments/Updates

Table 145. Uni-Bio Science Group Company Information

Table 146. Uni-Bio Science Group Description and Business Overview

Table 147. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 148. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product

Table 149. Uni-Bio Science Group Recent Developments/Updates

Table 150. Takeda Company Information

Table 151. Takeda Description and Business Overview

Table 152. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 153. Takeda Non-Insulin Hypoglycemic Drug Product

Table 154. Takeda Recent Developments/Updates

Table 155. 3SBio Company Information

Table 156. 3SBio Description and Business Overview

Table 157. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 158. 3SBio Non-Insulin Hypoglycemic Drug Product

Table 159. 3SBio Recent Developments/Updates

Table 160. Jiangsu Hengrui Medicine Company Information

Table 161. Jiangsu Hengrui Medicine Description and Business Overview

Table 162. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 163. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product

Table 164. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 165. Key Raw Materials Lists

Table 166. Raw Materials Key Suppliers Lists

Table 167. Non-Insulin Hypoglycemic Drug Distributors List

Table 168. Non-Insulin Hypoglycemic Drug Customers List

Table 169. Non-Insulin Hypoglycemic Drug Market Trends

Table 170. Non-Insulin Hypoglycemic Drug Market Drivers

Table 171. Non-Insulin Hypoglycemic Drug Market Challenges

Table 172. Non-Insulin Hypoglycemic Drug Market Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

Table 176. Authors List of This Report

List of Figures

Figure 1. Product Picture of Non-Insulin Hypoglycemic Drug

Figure 2. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-Insulin Hypoglycemic Drug Market Share by Type: 2024 & 2031

Figure 4. Sulfonylureas Product Picture

Figure 5. Meglitinides Product Picture

Figure 6. Biguanides Product Picture

Figure 7. Thiazolidinediones Product Picture

Figure 8. Alpha Glucosidase Inhibitors Product Picture

Figure 9. Others Product Picture

Figure 10. Global Non-Insulin Hypoglycemic Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Non-Insulin Hypoglycemic Drug Market Share by Application: 2024 & 2031

Figure 12. Hospital Pharmacies

Figure 13. Retail Pharmacies

Figure 14. Global Non-Insulin Hypoglycemic Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Non-Insulin Hypoglycemic Drug Market Size (2020-2031) & (US$ Million)

Figure 16. Global Non-Insulin Hypoglycemic Drug Sales (2020-2031) & (K Units)

Figure 17. Global Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) & (2020-2031)

Figure 18. Non-Insulin Hypoglycemic Drug Report Years Considered

Figure 19. Non-Insulin Hypoglycemic Drug Sales Share by Manufacturers in 2024

Figure 20. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Non-Insulin Hypoglycemic Drug Players: Market Share by Revenue in Non-Insulin Hypoglycemic Drug in 2024

Figure 22. Non-Insulin Hypoglycemic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2020-2031)

Figure 25. North America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2020-2031)

Figure 26. United States Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2020-2031)

Figure 29. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2020-2031)

Figure 30. Germany Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2020-2031)

Figure 37. China Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. China Taiwan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2020-2031)

Figure 45. Latin America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Non-Insulin Hypoglycemic Drug by Type (2020-2031)

Figure 55. Global Revenue Market Share of Non-Insulin Hypoglycemic Drug by Type (2020-2031)

Figure 56. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Non-Insulin Hypoglycemic Drug by Application (2020-2031)

Figure 58. Global Revenue Market Share of Non-Insulin Hypoglycemic Drug by Application (2020-2031)

Figure 59. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2020-2031)

Figure 60. Non-Insulin Hypoglycemic Drug Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions